Novavax, Inc.

How big is Novavax, Inc.?

As of Jun 18, Novavax, Inc. has a market capitalization of 1,054.81 million, classifying it as a Micro Cap company, with net sales of 1,254.95 million and a net profit of 478.70 million over the latest four quarters.

Market Cap: As of Jun 18, Novavax, Inc. has a market capitalization of 1,054.81 million, classifying it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Novavax reported net sales of 1,254.95 million and a net profit of 478.70 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company's shareholder's funds amounted to -623.84 million, while total assets were reported at 1,602.67 million.

What does Novavax, Inc. do?

Novavax, Inc. is a clinical-stage vaccine company specializing in recombinant nanoparticle vaccines and adjuvants. As of March 2025, it reported net sales of $667 million and a net profit of $519 million, with a market cap of approximately $1.05 billion.

Overview:<BR>Novavax, Inc. is a clinical-stage vaccine company focused on the discovery, development, and commercialization of recombinant nanoparticle vaccines and adjuvants within the Pharmaceuticals & Biotechnology industry.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 667 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 519 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 1,054.81 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 2.00 <BR>Dividend Yield: 0.00% <BR>Debt Equity: 7.49 <BR>Return on Equity: -647.88% <BR>Price to Book: -13.94 <BR><BR>Contact Details:<BR>Address: 21 Firstfield Rd, GAITHERSBURG MD: 20878-1757 <BR>Tel: 1 240 2682000 <BR>Website: http://www.novavax.com/

Should I buy, sell or hold Novavax, Inc.?

Who are in the management team of Novavax, Inc.?

As of March 2022, the management team of Novavax, Inc. includes Dr. James Young (Independent Chairman), Mr. Stanley Erck (President and CEO), and several directors: Mr. Gregg Alton, Dr. Rajiv Modi, Dr. Richard Douglas, Mr. Gary Evans, and Ms. Rachel King.

As of March 2022, the management team of Novavax, Inc. includes the following individuals:<BR><BR>- Dr. James Young: Independent Chairman of the Board<BR>- Mr. Stanley Erck: President, Chief Executive Officer, Director<BR>- Mr. Gregg Alton: Director<BR>- Dr. Rajiv Modi: Director<BR>- Dr. Richard Douglas: Independent Director<BR>- Mr. Gary Evans: Independent Director<BR>- Ms. Rachel King: Independent Director

Is Novavax, Inc. technically bullish or bearish?

As of October 3, 2025, Novavax, Inc. shows a bullish technical trend with strong short-term indicators, but long-term performance remains concerning with a 1-year return of -33.28%.

As of 3 October 2025, the technical trend for Novavax, Inc. has changed from mildly bullish to bullish. The current stance is bullish with strong indicators from the weekly MACD and Bollinger Bands, both signaling bullish momentum. Daily moving averages also confirm a bullish trend. However, the monthly KST and Dow Theory show mixed signals, indicating some caution. <BR><BR>In terms of performance, Novavax has outperformed the S&P 500 over the past week and month, returning 5.95% and 14.94% respectively, compared to the S&P's 1.09% and 4.15%. However, the longer-term returns are significantly negative, with a 1-year return of -33.28% versus the S&P's 17.82%. Overall, the current technical stance is bullish, but the long-term performance remains a concern.

Is Novavax, Inc. overvalued or undervalued?

As of October 17, 2025, Novavax, Inc. is considered undervalued with a P/E ratio of 2, an EV to EBITDA ratio of 1.38, and a PEG ratio of 0.01, significantly lower than industry peers, indicating potential for growth.

As of 17 October 2025, the valuation grade for Novavax, Inc. moved from expensive to fair. Based on the current metrics, the company appears to be undervalued. The P/E ratio stands at 2, significantly lower than the industry average, while the EV to EBITDA ratio is 1.38 and the PEG ratio is an exceptionally low 0.01, indicating potential for growth relative to its price.<BR><BR>In comparison with peers, Novavax's P/E ratio of 2.87 is notably lower than ADMA Biologics, Inc., which has a P/E of 18.56, highlighting a stark valuation discrepancy. Additionally, Novavax's EV to EBITDA ratio of 1.99 is also much lower than the industry average, reinforcing its undervaluation. Although return data is not available for a direct comparison with the S&P 500, the company's current valuation metrics suggest that it is positioned favorably in the market.